投稿回复语
论文——题目科学论文都有题目，不能“无题”。论文题目一般20字左右。题目大小应与内容符合，尽量不设副题，不用第1报、第2报之类。论文题目都用直叙口气，不用惊叹号或问号，也不能将科学论文题目写成广告语或新闻报道用语。
署名
(二)论文——署名科学论文应该署真名和真实的工作单位。主要体现责任、成果归属并便于后人追踪研究。严格意义上的论文作者是指对选题、论证、查阅文献、方案设计、建立方法、实验操作、整理资料、归纳总结、撰写成文等全过程负责的人，应该是能解答论文的有关问题者。往往把参加工作的人全部列上，那就应该以贡献大小依次排列。论文署名应征得本人同意。学术指导人根据实际情况既可以列为论文作者，也可以一般致谢。行政领导人一般不署名。
❷ 投稿时应说什么礼貌用语
普通问候就可以了，对象可以是某某杂志社负责人或者某某杂志编辑。然后注明内论文的基本资料容
如 所有作者真实姓名 通讯作者 联系方式 邮箱 学校地址 项目支持基金 投稿栏目 等。
有些杂志社是采用上传的方式收稿，到杂志主页上按照提示一步一步操作就可以了。
祝你好运！望采纳
❸ 如何回复SCI投稿审稿人意见
1.所有问题必须逐条回答。
2.尽量满足意见中需要补充的实验。
3.满足不了的也不要回避，说明不能做的合理理由。
4.审稿人推荐的文献一定要引用，并讨论透彻。
以下是本人对审稿人意见的回复一例，仅供参考。
续两点经验：
1. 最重要的是逐条回答，即使你答不了，也要老实交代；不要太狡猾，以至于耽误事；
2. 绝大部分实验是不要真追加的，除非你受到启发，而想改投另外高档杂志----因为你既然已经写成文章，从逻辑上肯定是一个完整的 “story” 了。
以上指国际杂志修稿。国内杂志太多，以至于稿源吃紧，基本没有退稿，所以你怎么修都是接受。
我的文章水平都不高，主要是没有明显的创新性，也很苦恼。但是除了开始几篇投在国内杂志外，其他都在国际杂志（也都是SCI）发表。以我了解的情况，我单位其他同志给国内杂志投稿，退稿的极少，只有一次被《某某科学进展》拒绝。究其原因，除了我上面说的，另外可能是我单位写稿子还是比较严肃，导师把关也比较严的缘故。
自我感觉总结（不一定对）：
1）国内杂志审稿极慢（少数除外），但现在也有加快趋势；
2）国内杂志编辑人员认真负责的人不多，稿子寄去后，少则几个月，多则一年多没有任何消息；
3）国内杂志要求修改的稿子，如果你自己不修，他最后也给你发；
4）国外杂志要求补充实验的，我均以解释而过关，原因见少帖）。还因为：很少杂志编辑把你的修改稿再寄给当初审稿人的，除非审稿人特别请求。编辑不一定懂你的东西，他只是看到你认真修改，回答疑问了，也就接受了（当然高档杂志可能不是这样，我的经验只限定一般杂志（影响因子1-5）。
欢迎大家批评指正。
我常用的回复格式:
Dear reviewer:
I am very grateful to your comments for the manuscript. According with your advice, we amended the relevant part in manuscript. Some of your questions were answered below.
1）
2）
....
引用审稿人推荐的文献的确是很重要的，要想办法和自己的文章有机地结合起来。
至于实验大部分都可以不用补做，关键是你要让审稿人明白你的文章的重点是什么，这个实验对你要强调的重点内容不是很必要，或者你现在所用的方法已经可以达到目的就行了。
最后要注意，审稿人也会犯错误，不仅仅是笔误也有专业知识上的错误，因为编辑找的审稿人未必是你这个领域的专家。只要自己是正确的就要坚持。在回复中委婉地表达一下你的意见，不过要注意商讨语气哦！
我得回复格式是这样的：
Dear Professor xx:
Thank you very much for your letter dated xxx xx xxxx, and the referees’ reports. Based on your comment and request, we have made extensive modification on the original manuscript. Here, we attached revised manuscript in the formats of both PDF and MS word, for your approval. A document answering every question from the referees was also summarized and enclosed.
A revised manuscript with the correction sections red marked was attached as the supplemental material and for easy check/editing purpose.
Should you have any questions, please contact us without hesitate.
然后再附上Q/A，基本上嘱条回答，写的越多越好（老师语）。结果修改一次就接收了：）
我的回复，请老外帮忙修改了
Dear Editor:
Thank you for your kind letter of “......” on November **, 2005. We revised the manuscript in accordance with the reviewers’ comments, and carefully proof-read the manuscript to minimize typographical, grammatical, and bibliographical errors.
Here below is our description on revision according to the reviewers’ comments.
Part A (Reviewer 1)
1. The reviewer’s comment: ......
The authors’ Answer: .....
2. The reviewer’s comment: ......
The authors’ Answer: .....
...
...
Part B (Reviewer 2)
1. The reviewer’s comment: ......
The authors’ Answer: .....
2. The reviewer’s comment: ......
The authors’ Answer: .....
...
...
Many grammatical or typographical errors have been revised.
All the lines and pages indicated above are in the revised manuscript.
Thank you and all the reviewers for the kind advice.
Sincerely yours,
***
一个回复的例子(已接收)
Major comments:
1. The authors need to strengthen their results by including MMP secretion, and tran-matrigel migration by a positive control progenitor cell population i.e. enriched human CD34 cells obtained from mobilized PBL, since this is a more clinically relevant source of CD34 cells which has also been shown to secrete both MMP-9 and MMP-2 (ref. 11). CD34 enriched cells from steady state peripheral blood which also secrete MMPs are also of interest.
2. In fig 1C please specify which cell line represents MMP-negative cells. This needs to be clarified, as well as a better explanation of the method of the protocol.
3. The ELISA results are represented as "fold increase" compared to control. Instead, we suggest that standards should be used and results should be presented as absolute concentrations and only then can these results be compared to those of the zymography.
4. When discussing the results, the authors should distinguish clearly between spontaneous migration vs chemotactic migration. Furthermore, the high spontaneous migration obtained with cord blood CD34 cells should be compared to mobilized PBL CD34 enriched cells and discussed.
5. The authors claim that the clonogenic assay was performed to determine the optimum concentration for inhibition of MMP activity by phenanthroline and anti MMP-9 mAb, however they should clarify that this assay can only determine the toxicity of the inhibitors and not their optimal inhibitory concentrations.
Minor comments:
1. There are many spelling and syntax errors, especially in the results and discussion, which need correction.
a. Of special importance, is the percent inhibition of migration, which is described as percent of migration. i.e. pg 7:"Migration of CB CD34 was reced to 73.3%?" Instead should read "Migration of CB CD34 was reced by 73.3%?"
b. The degree symbol needs to be added to the numbers in Materials and methods.
2. It would be preferable to combine figure 1A and B, in order to confirm the reliability of fig. 1B by a positive control (HT1080).
Answer to referee 1 comment:
1. Mobilized peripheral blood is a more clinical source of CD34+ cells, so it is necessary to compare the MMP-9 secretion and trans-migration ability of CB CD34+ cells with that of mobilized PB CD34+ cells. However, we couldn't obtain enough mobilized PB to separate PB CD34+ cells and determine the MMP-9 secretion and migration ability, so we couldn’t complement the study on PB CD34+ cells in this paper. Results obtained by Janowska-Wieczorek et al found that mobilized CD34+ cells in peripheral blood express MMP-9. Furthermore, Domenech’s study showed that MMP-9 secretion is involved in G-CSF inced HPC mobilization. Their conclusions have been added in the discussion. In our present study, our central conclusion from our data is that freshly isolated CD34+ stem/progenitor cells obtained from CB proce MMP-9.
2. MMP-9 negative cell used in fig 1C was Jurkat cell. In zymographic analysis, MMP-9 was not detected in the medium conditioned by Jurkat cell. To exclude that the contaminating cells may play a role in the observed MMP-9 proction, we screened the media conditioned by different proportion of CB mononuclear cells with MMP-9 negative cells by zymography. This result may be confusion. Actually, only by detecting the medium conditioned by 2X105 CB mononuclear cells (MNC)/ml (since the purities of CD34+ cell are more than 90%), it could exclude the MNC role. In the revised manuscript, we only detected MMP-9 activity and antigen level in the medium conditioned by 2X105 CB mononuclear cells (MNC)/ml. There is no MMP-9 secretion be detected in the medium conditioned by 2X105 CB MNC/ml. It excluded the possibility that the MMP-9 activity in CB CD34+ cells conditioned medium is e to the contamination by MNC.
3.In this revised paper, we have detected the MMP-9 antigen levels by using commercial specific ELISA kits (R&D System, sensitivity, 0.156ng/ml). Recombinant MMP-9 from R&D System was used as a standard. The results are expressed in the absolute concentration. The absolute concentration result has been added in the paper. As shown in Fig2, MMP-9 levels were detectable in both CB CD34+ cell conditioned medium and BM CD34+ cell conditioned medium. However, MMP-9 level was significantly higher in CB CD34+ cell conditioned medium than in BM CD34+ cell conditioned medium (0.406±0.133ng/ml versus 0.195±0.023ng/ml). Although gelatinolytic activity was not detected in media conditioned by CD34+ cells from BM, sensitivity of ELISA favors the detection of MMP-9 antigen in the BM CD34+.
4. In our study, to establish the direct link between MMP-9 and CB CD34+ cells migration, we only determined the role of MMP-9 in spontaneous migration of CB CD34+ cells, but not in chemotactic migration. Actually, regulation of hematopoietic stem cell migration, homing and anchorage of repopulation cells to the bone marrow involves a complex interplay between adhesion molecules, chemokines, cytokines and proteolytic enzymes. Results obtained by the groups of Voermans reveal that not only the spontaneous migration but also the SDF-1 inced migration of CB CD34+ cells is greatly increased in comparison to CD34+ cells from BM and peripheral blood.
5. CD34+ cells we obtained in each cord blood sample were very limited. It is not enough to screen the inhibitors concentrations to select the optimal inhibitory concentrations. In the blocking experiments, based on the concentrations used by others and the manufacturer's recommendation, we then determined the inhibitors concentrations by excluding the toxicity of the inhibitors in that concentration, which was determined by clonogenic assay.
Minor comments:
1.The spelling and syntax errors have been checked and corrected.
2.Since the results in figure 1A and B were obtained from two separated and parallel experiments, it is not fitness to combine two figures.
❹ 投稿信怎么写
Cover Letter 既投稿信，对于科研论文新手来说，不知该如何下手，而对于论文老司机来说，重视程度普遍比较低。查尔斯沃思论文润色在往期的文章中多次介绍过投稿信的重要性（参见《投稿信的重要性》），投稿信可以告诉杂志及其编辑为什么他们应该考虑你的文章。这是特别重要的，因为当初审编辑在筛选你的论文时，就此决定是否在同行评审环节中寻找特定的专家，所以期刊欢迎增加对你研究的简要总结。
不同的期刊对投稿信的要求各不相同，例如有的杂志会要求推荐几位审稿人。一般会在杂志的作者指南（guide for authors）中看到具体的要求。许多作者并没有注意到投稿信的重要性，即便它的重要性已经成为常识问题。有些作者甚至对此有一些误解。
投稿信应包含哪些内容？这一问题在《投稿信的重要性》中已经有给出了详细的说明，在此再次强调一下，除了一些基本信息外，最主要的是把该篇论文的研究重点及学术贡献、创意简洁的强调下。
我们也为大家准备了一个通用模板，供作者参考，该模板来自SPIE：
[Your Name]
[Your Affiliation]
[Your Address]
[Date]
Dear Dr.[Editor name],
I/We wish to submit a new manuscript entitled “[title of article]” for consideration by the [journal name].
I/We confirm that this work is original and has not been published elsewhere nor is it currently under consideration for publication elsewhere.
In this paper, I/we report on . This is significant because . The paper should be of interest to readers in the areas of .
[Please explain in your own words the significance and novelty of the work, the problem that is being addressed, and why the manuscript belongs in this journal. Do not simply insert your abstract into your cover letter! Briefly describe the research you are reporting in your paper, why it is important, and why you think the readership of the journal would be interested in it.]
Please address all correspondence concerning this manuscript to me at [email address].
Thank you for your consideration of this manuscript.
Sincerely,
[Yourname]
❺ 给杂志社投稿怎么写邮件正文
首先，在邮件的正题内里一般要标明：投稿（有的人是提建议啊什么的，这样便于编辑区分！）、投稿的栏目（如果你很熟悉那本杂志，或者那本杂志的征稿讯息很详细，肯定是要标明栏目，这一点是加印象分的关键！）还有就是作品名称（便于日后编辑找到你的稿子）。以上是最基本的三要素。
然后就是正文了，一般可以加一些问候之类的言语，但不要太多。粘贴文章（注：一般都把自己的文章直接粘贴在正文中，没有特殊要求，不要以附件形式发送。还有，要以简朴为主，不要搞什么信纸啊，插图啊）
最后，在末尾留下你的联系方式，一般采用这个格局：
真名： 笔名：
地址：
邮编：
邮箱:
QQ：
（越详细越好）
这样，编辑就可以很方便的在人山人海中找到联系你的方式了！
❻ 请别人积极投稿要用什么敬词
请别人积极投稿，你可以用敬词，你可以这样表达的，尊敬的同学，请你们积极投稿，有丰富的奖品等你们来参加
❼ 写一则宣传语,鼓励同学积极投稿
相信自己，鼓励自己，超越自己。为太阳的光辉在添上永恒的一笔！来显示你的才华，来展示你的风采，来比拼你的实力！！赏五湖四海，读天下文章，欢迎大家踊跃投稿！！
❽ 如果私信投稿语气激动无礼质疑,不理解者你会如何回复
我一般都会选择不理会
❾ 如何回复审稿人关于语言方面的问题
1、所有问题必须逐条回答。
2、尽量满足意见中需要补充的实验。
3、满足不了的也不要回避，说明不能做的合理理由。
4、审稿人推荐的文献一定要引用，并讨论透彻。
5、对于审稿人提出要补充的实验，如果不是非做不可的，还是可以进行解释。有时审稿人即使想接受你的文章，总还要提出一些不足之处，如果文章没有那些不足之处，也许文章就会投给更高的杂志了。所以，如果你真的不想补充实验或者补充很困难，可以合理的解释，一般没问题的。